Literature DB >> 25404125

HDL cholesterol efflux capacity and incident cardiovascular events.

Anand Rohatgi1, Amit Khera, Jarett D Berry, Edward G Givens, Colby R Ayers, Kyle E Wedin, Ian J Neeland, Ivan S Yuhanna, Daniel R Rader, James A de Lemos, Philip W Shaul.   

Abstract

BACKGROUND: It is unclear whether high-density lipoprotein (HDL) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of HDL to accept cholesterol from macrophages, which is a key step in reverse cholesterol transport. We investigated the epidemiology of cholesterol efflux capacity and its association with incident atherosclerotic cardiovascular disease outcomes in a large, multiethnic population cohort.
METHODS: We measured HDL cholesterol level, HDL particle concentration, and cholesterol efflux capacity at baseline in 2924 adults free from cardiovascular disease who were participants in the Dallas Heart Study, a probability-based population sample. The primary end point was atherosclerotic cardiovascular disease, defined as a first nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization or death from cardiovascular causes. The median follow-up period was 9.4 years.
RESULTS: In contrast to HDL cholesterol level, which was associated with multiple traditional risk factors and metabolic variables, cholesterol efflux capacity had minimal association with these factors. Baseline HDL cholesterol level was not associated with cardiovascular events in an adjusted analysis (hazard ratio, 1.08; 95% confidence interval [CI], 0.59 to 1.99). In a fully adjusted model that included traditional risk factors, HDL cholesterol level, and HDL particle concentration, there was a 67% reduction in cardiovascular risk in the highest quartile of cholesterol efflux capacity versus the lowest quartile (hazard ratio, 0.33; 95% CI, 0.19 to 0.55). Adding cholesterol efflux capacity to traditional risk factors was associated with improvement in discrimination and reclassification indexes.
CONCLUSIONS: Cholesterol efflux capacity, a new biomarker that characterizes a key step in reverse cholesterol transport, was inversely associated with the incidence of cardiovascular events in a population-based cohort. (Funded by the Donald W. Reynolds Foundation and others.).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404125      PMCID: PMC4308988          DOI: 10.1056/NEJMoa1409065

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  28 in total

Review 1.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

2.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 3.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

5.  Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow.

Authors:  Mollie Ranalletta; Nan Wang; Seongah Han; Laurent Yvan-Charvet; Carrie Welch; Alan R Tall
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-17       Impact factor: 8.311

6.  Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow.

Authors:  Angel Baldán; Liming Pei; Richard Lee; Paul Tarr; Rajendra K Tangirala; Michael M Weinstein; Joy Frank; Andrew C Li; Peter Tontonoz; Peter A Edwards
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-03       Impact factor: 8.311

7.  Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling.

Authors:  Chatchawin Assanasen; Chieko Mineo; Divya Seetharam; Ivan S Yuhanna; Yves L Marcel; Margery A Connelly; David L Williams; Margarita de la Llera-Moya; Philip W Shaul; David L Silver
Journal:  J Clin Invest       Date:  2005-03-24       Impact factor: 14.808

8.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

9.  African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study.

Authors:  Tulika Jain; Ronald Peshock; Darren K McGuire; DuWayne Willett; Zhoaxia Yu; Zhoazia Yu; Gloria L Vega; Rudy Guerra; Helen H Hobbs; Scott M Grundy
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

10.  The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health.

Authors:  Ronald G Victor; Robert W Haley; DuWayne L Willett; Ronald M Peshock; Patrice C Vaeth; David Leonard; Mujeeb Basit; Richard S Cooper; Vincent G Iannacchione; Wendy A Visscher; Jennifer M Staab; Helen H Hobbs
Journal:  Am J Cardiol       Date:  2004-06-15       Impact factor: 2.778

View more
  455 in total

Review 1.  Time to ditch HDL-C as a measure of HDL function?

Authors:  Graziella E Ronsein; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

2.  HDL: Beyond Atheroprotection.

Authors:  Valentina Kon; MacRae F Linton
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

3.  HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Authors:  Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar
Journal:  J Lipid Res       Date:  2015-08-07       Impact factor: 5.922

4.  Refocusing the AIM on HDL in the metabolic syndrome.

Authors:  Robert W McGarrah
Journal:  Atherosclerosis       Date:  2016-07-02       Impact factor: 5.162

5.  Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause.

Authors:  Samar R El Khoudary; Patrick M Hutchins; Karen A Matthews; Maria M Brooks; Trevor J Orchard; Graziella E Ronsein; Jay W Heinecke
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

6.  HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Robin P F Dullaart; Jan-Stephan F Sanders; Stephan J L Bakker; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

Review 7.  Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.

Authors:  Michael V Holmes; Mika Ala-Korpela; George Davey Smith
Journal:  Nat Rev Cardiol       Date:  2017-06-01       Impact factor: 32.419

Review 8.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

9.  Increase HDL-C level over the menopausal transition is associated with greater atherosclerotic progression.

Authors:  Samar R El Khoudary; Lin Wang; Maria M Brooks; Rebecca C Thurston; Carol A Derby; Karen A Matthews
Journal:  J Clin Lipidol       Date:  2016-04-26       Impact factor: 4.766

10.  Impaired Renal Function on Cholesterol Efflux Capacity, HDL Particle Number, and Cardiovascular Events.

Authors:  Shahzad Chindhy; Parag Joshi; Amit Khera; Colby R Ayers; S Susan Hedayati; Anand Rohatgi
Journal:  J Am Coll Cardiol       Date:  2018-08-07       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.